Outcome of Botulinum Toxin Treatment for Oromandibular Dystonia

Dystonia; Orofacial Clinical Trial

— rétroBODOM  

Official title:

Outcome of Botulinum Toxin Treatment for Oromandibular Dystonia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03363113
• Other study ID #: CE_20150630_7_LSM
• Status: Completed
• Phase: N/A
• First received: November 30, 2017
• Last updated: November 30, 2017
• Start date: January 1, 2016
• Est. completion date: July 12, 2016

Study information

• Verified date: November 2017
• Source: Fondation Ophtalmologique Adolphe de Rothschild
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Symptoms of oromandibular dystonia can be alleviated by injections of botulinum toxin. The scope of this study is to describe the efficacy of this procedure, by a retrospective systematic review of patients medical charts

Recruitment information / eligibility

• Status: Completed
• Enrollment: 240
• Est. completion date: July 12, 2016
• Est. primary completion date: April 1, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient suffering from oromandibular dystonia

• Medical follow up in the Fondation Ophtalmologique Rothschild (Paris)

• Treatment by at least one session of botulinum toxin injection

Exclusion Criteria:

• Patient cannot assess symptoms improvement using a Likert scale

Related Conditions & MeSH terms

• Dystonia
• Dystonia; Orofacial
• Dystonic Disorders

Intervention

Drug:
• Botulinum Toxins
Injection of botulinum toxin in the muscles affected by oromandibular dystonia

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Fondation Ophtalmologique Adolphe de Rothschild

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical improvement score	Likert scale for the assessment of the clinical improvement after treatment	Two months